Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

IL13RA2 Antikörper

IL13RA2 Reaktivität: Human ELISA, IHC, FACS Wirt: Maus Monoclonal B-D13 unconjugated
Produktnummer ABIN1383686
  • Target Alle IL13RA2 Antikörper anzeigen
    IL13RA2 (Interleukin 13 Receptor, alpha 2 (IL13RA2))
    Reaktivität
    • 62
    • 26
    • 10
    • 7
    • 4
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 52
    • 8
    • 3
    Maus
    Klonalität
    • 57
    • 6
    Monoklonal
    Konjugat
    • 30
    • 5
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser IL13RA2 Antikörper ist unkonjugiert
    Applikation
    • 49
    • 24
    • 16
    • 9
    • 4
    • 4
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    ELISA, Immunohistochemistry (IHC), Flow Cytometry (FACS)
    Spezifität
    Recognises the IL-13 receptor a2 (IL-13 Ra2), a 44 kDa protein
    Aufreinigung
    Ion exchange chromatography
    Sterilität
    0.22 μm filtered
    Immunogen
    IL-13Ra2 transfected CHO cell line,Myeloma X63/AG.8653 x Balb/c spleen cells
    Klon
    B-D13
    Isotyp
    IgG1 kappa
    Top Product
    Discover our top product IL13RA2 Primärantikörper
  • Applikationshinweise
    Optimal working dilution should be determined by the investigator.
    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Liquid
    Buffer
    Phosphate-buffered saline. Sterile-filtered through 0.22 μm. Carrier and preservative free
    Konservierungsmittel
    Without preservative
    Lagerung
    4 °C
    Informationen zur Lagerung
    Stable at +2-8°C for 12 months. For longer storage freeze aliquots.
  • Kawakami, Terabe, Kioi, Berzofsky, Puri: "Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 15, pp. 4678-86, (2006) (PubMed).

    Kawakami, Kawakami, Puri: "Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease." in: Molecular cancer therapeutics, Vol. 3, Issue 2, pp. 137-47, (2004) (PubMed).

    Blanchard, Durual, Estienne, Bouzakri, Heim, Blin, Cuber: "IL-4 and IL-13 up-regulate intestinal trefoil factor expression: requirement for STAT6 and de novo protein synthesis." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 172, Issue 6, pp. 3775-83, (2004) (PubMed).

    Kawakami, Kawakami, Kasperbauer, Hinkley, Tsukuda, Strome, Puri: "Interleukin-13 receptor alpha2 chain in human head and neck cancer serves as a unique diagnostic marker." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 9, Issue 17, pp. 6381-8, (2003) (PubMed).

    Joshi, Kawakami, Leland, Puri: "Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 8, Issue 6, pp. 1948-56, (2002) (PubMed).

    Lordan, Bucchieri, Richter, Konstantinidis, Holloway, Thornber, Puddicombe, Buchanan, Wilson, Djukanović, Holgate, Davies: "Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 169, Issue 1, pp. 407-14, (2002) (PubMed).

    Kawakami, Kawakami, Puri: "IL-13 receptor-targeted cytotoxin cancer therapy leads to complete eradication of tumors with the aid of phagocytic cells in nude mice model of human cancer." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 169, Issue 12, pp. 7119-26, (2002) (PubMed).

    Joshi, Plautz, Puri: "Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas." in: Cancer research, Vol. 60, Issue 5, pp. 1168-72, (2000) (PubMed).

  • Target
    IL13RA2 (Interleukin 13 Receptor, alpha 2 (IL13RA2))
    Andere Bezeichnung
    CD213a2 (IL13RA2 Produkte)
    Synonyme
    il-13ra2 antikoerper, sb:cb602 antikoerper, si:dkeyp-110c7.6 antikoerper, CD213A2 antikoerper, CT19 antikoerper, IL-13R antikoerper, IL13BP antikoerper, CD213a2 antikoerper, IL-13R-alpha-2 antikoerper, IL13RA2 antikoerper, interleukin 13 receptor, alpha 2 antikoerper, interleukin 13 receptor subunit alpha 2 antikoerper, interleukin 13 receptor subunit alpha 2 S homeolog antikoerper, il13ra2 antikoerper, IL13RA2 antikoerper, il13ra2.S antikoerper, Il13ra2 antikoerper
    Hintergrund
    IL-13Ra2
    Molekulargewicht
    74 kDa
Sie sind hier:
Kundenservice